Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
This article was originally published in The Gray Sheet
Executive Summary
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.